Helen Frankenthaler Foundation

Ghrelin pentapeptide analog supplier

Pharmaceutical Peptide, Research Peptides, Synthetic Peptides

Pharmaceutical Peptide, Research Peptides, Synthetic Peptides - Go Top

Research - Development - Production

A national high-tech enterprise specializing in R&D and production of peptides and related derivatives.

About us

Hangzhou Go Top Peptide Biotech Co., Ltd. was founded in 2014, is a national high-tech enterprise specializing in R&D and production of peptides and related derivatives. It is also a governing unit of Polypeptide Branch of China Biochemical and Pharmaceutical Industry Association. At present, the company has a peptide research and development center in Hangzhou, covering an area of more than 4,000 square meters, and two commercial peptide factories in Shangyu and Anji, Zhejiang, with several complete peptide production lines, several sets of large-scale peptide synthesis equipment, imported HPLC analysis and preparation equipment, and equipped with a GMP standard clean laboratory. The company has passed the ISO9001:2015 quality management system certification.

Our Products

Browse by: All

Products

  • Pharmaceutical Peptide
  • Cosmetic Peptide
  • Catalog peptide
  • custom peptide synthesis
Cyclo(Phe-Val)/14474-71-6/Peptide customization
FOXO4-DRI Customized Peptide
Customization of High Purity vosoritide
High purity peptide PE-22-28
High-purity ARA290 Peptide Chinese Manufacturer
AHK-Cu,Cas 682809-81-0,Chinese Peptide Maunfacturer
Cartalax high purity research peptides
Epithalon/307297-39-8/Bacterial endotoxins
Melanotan I/75921-69-6/Peptide purification
Larazotide/258818-34-7/Peptide test

Our News

New Research Suggests GLP-1 Receptor Agonists May Improve Knee Osteoarthritis Beyond Weight Loss

New research suggests semaglutide, a GLP-1 receptor agonist, may improve knee osteoarthritis by supp...

The Sapphire of Skin Repair — Why Is Copper Peptide So Popular?

The Story of Copper PeptideIn 1973, American biochemist Loren Pickart discovered a naturally oc...

Novo Nordisk-partnered drug shows 19.7% weight loss in Phase II trial

UBT251 is being jointly developed by United Bio-Technology and Novo Nordisk under a March 2025 agree...

New Hope Against Multidrug-Resistant Pseudomonas aeruginosa:Scientific Breakthrough of Murepavadin.

In the face of increasingly severe multidrug-resistant bacterial infections, the development progres...